This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
Some patients may not be suitable for PRODUODOPA. You are strongly advised to read the Prescribing information (PI), and Summary of Product Characteristics (SmPC) which can be found via the links above, to evaluate patient suitability for PRODUODOPA.
PRODUODOPA resources
Hear about PRODUODOPA from leading experts, including the key clinical data, case studies, the Homecare Service and onboarding patients onto PRODUODOPA.
The content on this page contain information about DUODOPA. Please refer to the DUODOPA Prescribing Information for more information about this product.
Patient suitability and practical considerations for PRODUODOPA treatment
Professor Camille Carroll, Principal Investigator of the clinical trials investigating PRODUODOPA at University Hospitals Plymouth and Professor of clinical neuroscience at Newcastle University, offers insight into identifying suitable patients for PRODUODOPA treatment and clinical practicalities of implementing the therapy.
This is a recording from a promotional meeting.
Initiating PRODUODOPA treatment: Centre-based case studies of onboarding experiences
A panel discussion involving representatives from three of the first UK centres to employ PRODUODOPA in their services, who compare patient cases studies and experiences, offering insight and advice to Parkinson’s Disease healthcare professionals.
This is a recording from a promotional meeting.
Diving into the data: Efficacy and safety of PRODUODOPA
Professor K Ray Chaudhuri, Director of the Parkinson Foundation International Centre of Excellence at King’s College London and contributor to the global development of the PRODUODOPA infusion, presents the efficacy and safety results from key PRODUODOPA clinical trials.
This is a recording from a promotional meeting.
Running a PRODUODOPA service: My centre’s experience
Professor Stephen Mullin, Neurology Consultant and Movement Disorder Specialist at University Hospital of Plymouth NHS trust, describes the process by which the Trust implemented and scaled the PRODUODOPA service in the South-West Peninsula, and shares details on how discussions with stakeholders have shaped the service.
This is a recording from a promotional meeting.
This page will be updated regularly. Visit again at a later date for more resources.
Please refer to the PRODUODOPA Summary of Product Characteristics (SmPC) for further information on adverse events, contraindications and special warnings and precautions for use.
References
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) Summary of Product Characteristics.
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-PRODD-240202. Date of preparation: December 2024.
